Introduction: Recent work has begun to elucidate the pathogenesis of intracranial aneurysms (IA) and has shown that many genes are involved in the risk for this condition. There has also been increasing research interest in the renin-angiotensin system (RAS) in the brain and its involvement in a range of cardiovascular and neurological disorders. The possibility that the RAS is implicated in the pathogenesis of IA merits further investigation. The aim of this article is to review the literature on the pathogenesis of IA and the pathophysiological significance of the brain RAS, and to identify directions for research into their association. Methods and results: A survey of the literature in these fields shows that although factors contributing to systemic hypertension predispose to IA, a large number of genes involved in endothelial cell adhesion, smooth muscle activity, extracellular matrix dynamics and the inflammatory and immune responses are also implicated. The brain RAS has a significant role in regulating blood pressure and in maintaining cerebrovascular autoregulation, but angiotensin II receptors are also involved in the maintenance of endothelial cell and vascular smooth muscle function and in the inflammatory response in the brain. Conclusions: There is strong, albeit largely circumstantial, evidence in the literature for a relationship between the brain RAS and the formation of IA. Research on the association between polymorphisms in RAS-related genes and the incidence of unruptured and ruptured IA is indicated.
Introduction
The pathogenesis of intracranial (cerebral) aneurysms (IAs) has been partially elucidated in recent years. The nature and pathophysiological significance of the brain reninangiotensin system (RAS) has also been explored. Evidence from both fields indicates that the RAS is among the many factors involved in the formation and probably the rupture of IAs. Further research focusing on the RAS-IA relationship is merited.
This review is organised as follows. The nature of IAs is briefly summarised and the current understanding of their pathogenesis is discussed, with an emphasis on the multiple genetic factors that predispose an individual to the disease. The physiology of the RAS is then summarised and the present-day knowledge of its role in the brain is considered in greater detail. Evidence implicating the RAS in the pathogenesis of IA is then reviewed, and a potential direction for further research is outlined. infection 4 and head and neck tumours. 5 Other risk factors include circumstances contributing to hypertension, such as atherosclerosis, cigarette smoking and drug or alcohol abuse. [4] [5] [6] [7] IAs are classified as saccular ('berry aneurysms'), lateral (dissecting) and fusiform, and they may range in size from less than 11 mm to greater than 25 mm. 8 Among patients with very small aneurysms (≤ 7 mm), hypertension, relatively young age and involvement of the posterior circulation appear to be significant risk factors for rupture. 9 Women are more susceptible to the condition than men. 6 IAs (particularly saccular aneurysms) are usually asymptomatic unless they rupture. 10 Common symptoms of rupture include violent headache, visual disturbance, photophobia, nausea and vomiting. Ruptured IA has an incidence of approximately 10 per 100,000 persons per year and is most common among people aged 30-60 years. 6, [11] [12] [13] The risk of rupture is increased by hypertension and by the location and size of the aneurysm. Diagnosis may be confirmed by intracerebral angiography, computed tomography (CT) or magnetic resonance imaging (MRI) scans and cerebrospinal fluid (CSF) analysis. 14 Treatment may be surgical, usually microvascular clipping or arterial occlusion, or by endovascular embolisation. 15, 16 Some 90% of all IAs are saccular and these are the major cause of morbidity and mortality, notably from subarachnoid haemorrhage. 11, 17 A longer-term post-rupture complication is cerebral artery vasospasm. 18 Saccular aneurysms develop from alterations in the lamina elastica interna and defects in the tunica muscularis, which make the arteries less resistant to changes in intraluminal pressure. 19 They are most common at sites of vessel bifurcation, notably the Circle of Willis (figure 1), where blood flow is turbulent and shear forces on the arterial walls are maximal. 20 Some 30% of patients develop multiple aneurysms. 21 In contrast, fusiform aneurysms develop from ectatic, tortuous arteries, typically in the vertebrobasilar system, often resulting in symptoms of cranial nerve or brainstem compression but seldom causing subarachnoid haemorrhage. 21 Dissecting aneurysms are the result of cystic medial necrosis or a traumatic tear in an arterial wall, and like dissecting aortic aneurysms, they entail collapse of the lumen. 19 
Pathogenesis of intracranial aneurysms
The pathogenic basis of abdominal aortic aneurysm (AAA) has been well studied, but there has been relatively little research on the pathogenesis of IA. Despite some aetiological commonality, the two processes are mechanistically distinct. 22 Humphrey and Taylor reviewed their many shared biomechanical and histochemical characteristics, but observed that AAAs and IAs result from different underlying disease processes. They focused on biomechanical aspects of pathogenesis, arguing for a need to couple studies of haemodynamics with studies of wall mechanics rather than considering them separately, and calling for a new class of computational models (fluid-solid-growth models) for this purpose. 23 A recent review by Norman and Powell emphasised our lack of knowledge of the underlying causes of most aneurysms, though up-regulated proteolytic pathways, inflammation, and degradation of the arterial wall matrix have been implicated in both IA and AAA. Gradual expansion of an aneurysm can lead to thrombosis and possibly distal embolisation as well as rupture. 24 In IA but not AAA, mRNA and protein expression of RAS components is down-regulated; in the latter but not the former, inhibition of matrix metalloproteinases (MMPs) ameliorates aneurysm expansion 22 .
Extracellular matrix degradation, apoptosis and inflammation in the pathogenesis of IA
Consistent with the view that wall elasticity and shear stress (incident on hypertension) are important pathogenic factors, there is evidence implicating variations in vessel geometry, 23, 25 and MMP activity in the extracellular matrix (ECM), in the causation of aneurysms. Some MMPs attack elastic fibres in the arterial wall, 26 altering the wall's tensile properties. Tissue inhibitors of MMPs (TIMPs) are protective against the development of IA. TIMP-1 and TIMP-2 in arterial walls are down-regulated early in the pathogenic process, while MMP activity is markedly elevated at a later stage. The imbalance between TIMP and MMP activities may be a major factor in ECM degradation during the formation of IA. 27 Jayaraman et al. 28 found that tumour necrosis factoralpha (TNFα) and the Fas death pathway were up-regulated in weakened cerebral arterial walls, though interleukin-10 (IL-10) was not, implying the involvement of apoptosis in the pathogenesis of IA. Kilic et al. 29 found immunohistochemical evidence that transforming growth factor-alpha (TGFα) levels are lower in normal vessel walls than aneurysm walls, and that the fibronectin/laminin ratio is greater in ruptured than unruptured aneurysms.
Inflammation, and especially the recruitment of macrophages and neutrophils secreting endothelins and free radicals, is likely to be involved, and is considered to be a cause of vasospasm. 30 In view of the evidence implicating macrophage-mediated chronic inflammation in the pathogenesis of IA, Aoki et al. examined the role of NF-κB in the process, using experimentally induced IA in rats. 31 NF-κB was up-regulated in the cerebral artery walls early in pathogenesis, inducing the expression of genes involved in the recruitment and activation of macrophages. The same authors later showed that the synthesis of procollagens and the post-transcriptional oxidation of collagen lysine residues were significantly inhibited in IA walls and in cultured rat aorta smooth muscle cells. These effects appeared to result from up-regulation of IL-1β expression and were mediated through the NF-κB pathway. 32 In a recent review, these authors emphasised that induction of the inflammatory response and inflammatory cell infiltration are crucial in the formation of IA, and argued that antiinflammatory agents (particularly NF-κB antagonists) have potential value in treating the condition. 33 
Involvement of vasoconstrictors and sodium balance in the pathogenesis of IA
Boullin et al. 34 examined vasoconstrictor activity in serial samples of CSF from 10 patients undergoing aneurysm clipping within 48 h after subarachnoid haemorrhage. Serotonin, histamine, norepinephrine, epinephrine, acetylcholine and angiotensin II (Ang II) were eliminated as prime vasoconstrictor agents inducing cerebral vasospasm. Zhang et al. 35 found that sodium loading increased the incidence of IA in spontaneously hypertensive stroke-prone rats, and while the levels of interleukin (IL)-1β, IL-6 and Ang II were all significantly increased, IL-6 was the most significant factor in IA formation according to multivariate analysis.
Multiple genes are implicated in predisposition to intracranial aneurysm
During the past decade, information about haemodynamic regulation in cerebral blood vessels has given impetus to studies leading to the identification of gene variants that may be pathogenic. [36] [37] [38] [39] [40] Genetic predisposition to IA has long been suspected; 41, 42 multiple genetic and environmental factors contribute to the risk. 42, 43 The contribution of RAS gene polymorphisms to IA pathogenesis must therefore be viewed in a wider context. Since many interacting genes are involved, the contribution of each single gene to the pathogenesis of IA is small. 36 Efforts to elucidate susceptibility loci are hindered by issues common to complex genetic disorders: low penetrance, late onset, and uncertain modes of inheritance. Also, many IA lesions remain asymptomatic or undiagnosed. Zhang and Claterbuck 44 recommended comprehensive genome-wide association studies to identify the genetic loci underlying IA.
Several studies have shown linkages between IA and chromosomes 1p, 45 53, 55 Some of these regions -chromosome 7q11, 17cen, 19q13 and Xp22contain genes for elastin (ELN), nitric oxide synthetase 2A (NOS2A), apolipoprotein E (APOE) and angiotensin-I converting enzyme 2 (ACE2). Not all polymorphisms in these candidate genes are pathologically significant, however. Mineharu et al. 52 found no associations of IA with eight single nucleotide polymorphisms (SNPs) in ELN, eight in NOS2A, one in ACE2, or three epsilon alleles in APOE.
Genome-wide genotyping of Finnish, Dutch and Japanese IA patients by Bilguvar et al. 47 identified common SNPs on chromosomes 2q, 8q and 9p that were significantly associated with IA. The 9p locus, involving the gene for CDKN2A, is known to be associated with various arterial diseases including IA. The associated SNPs on 8q probably act via SOX17, which is required for formatting and maintaining endothelial cells (EC), suggesting a role in development and repair of the vasculature; CDKN2A may have a similar role. Yasuno et al. 40 subsequently found three new loci associated with IA in this data set: intervals near RBBP8 on 18q11.2, STARD13-KL on 13q13.1 and a gene-rich region on 10q24.32. They also confirmed the associations near SOX17 (8q11.23-q12.1) and CDKN2A-CDKN2B (9p21.3). Several of the putative risk genes are implicated in cell cycle progression, so effects on the proliferation and senescence of progenitor cell populations may cause alterations in vascular formation and repair.
Pera et al. 56 analysed global gene expression patterns in human cases of ruptured IA and unruptured IA in comparison with control arteries. Among the three groups 159 genes differed in expression, and 131 of them showed the same direction of change in both IA groups compared with controls. The biological processes most markedly affected in IA were: (1) muscle activity (down-regulated); (2) cell adhesion (down-regulated); and (3) the immune system and inflammatory response (up-regulated). The immune/ inflammatory process genes showed lower expression in ruptured than unruptured IA. These authors concluded that decreased expression of genes related to the muscle system and cell adhesion is important for IA pathogenesis, but the role of immune/inflammatory processes was less clear. Inflammatory mediators may effect healing in unruptured IA and protect against IA rupture. Li et al. 57 also examined global gene expression patterns using microarray technology and found significant up-regulation of genes related to the ECM (collagen types I, III, V and XI, and MMPs) and significant down-regulation of genes related to inflammation and the immune response in ruptured aneurysm walls. Glycine mutations in exons 24 and 25 of Col4a1, which encodes procollagen type IVα1, predisposes to smallvessel disease and intracellular haemorrhage. 58, 59 Shi et al. 60 compared gene expression in aneurysm walls and in superficial temporal arteries from six consecutive patients and found 326 genes with more than twofold differences in expression. The most important pathways affected were focal adhesion, ECM receptor interactions, cell communication, the inflammatory response and apoptosis. Variants in the genes for versican (CSPG2), perlecan (HSPG2), fibrillin 2 (FBN2) and collagen 4A1 (COL4A1) were found to be associated with IA in two studies of Dutch patients. 45 The associations with FBN2 and COL4A1 were not replicated in a Japanese IA population, but the other two associations were.
A genetic variant on chromosome 9p21 is related to both AAA and IA. 50 However, a study of SNPs by Baas et al. 61 showed that although variations in the genes for heparan sulfate proteoglycan 2 (HSPG2) and chondroitin sulfate proteoglycan 2 (CSPG2) increase susceptibility to IA, these loci are not associated with AAA. This illustrates the point made by Zhou et al.: 22 there are differences in the pathogenesis of aneurysms in the two locations, though there are also shared genetic risk factors.
The renin-angiotensin system Overview
The RAS is crucial for maintaining normal vasorelaxation/ vasoconstriction 62, 63 and also vascular wall integrity. 64 Dysfunction of this system has been implicated in systemic and local vascular diseases such as hypertension, atherosclerosis and aneurysms. 62, [65] [66] [67] The history of its discovery and elucidation has been described by Basso and Terragno. 68 Angiotensinogen, a 452-residue α2 globulin, is produced constitutively by the liver and its plasma levels are elevated by corticosteroids, thyroxin, oestrogen and Ang II. 69 Its physiological function depends mainly on its N-terminal sequence (DRVYIHPFHLVI). The enzyme renin, produced by the kidneys in response to decreased intrarenal blood pressure and decreased sodium and chloride delivery, cleaves angiotensinogen at the HL-VI bond in this sequence to liberate angiotensin I (DRVYIHPFHL). 70 An isoform of angiotensin-converting enzyme (ACE) removes the two C-terminal residues from angiotensin I to produce Ang II (DRVYIHPF). 71 ACE is widely distributed in the body, principally in capillary endothelia, and is most abundant in the lung. 72 
Cardiovascular actions of angiotensin II
Ang II is the main effector of the RAS and functions through angiotensin receptor types 1 (AT1) and 2 (AT2). 71, 73 Apart from its well-known effects on renal blood flow, glomerular filtration, renal proximal tubule function and the adrenal cortex (aldosterone secretion), Ang II is a platelet activator. Most importantly for the present review, it exerts a vasoconstrictor action via AT1 receptors on vascular smooth muscle cells (VSMCs) 74 by stimulating the Gq protein, which activates muscle contraction by a mechanism involving IP3, 75 leading to rapid mobilisation of intracellular calcium and influx of extracellular calcium. 76 Activation of VSMC AT1 receptors also promotes DNA and contractile protein synthesis leading to VSMC proliferation and medial hypertrophy. 62, 77 There is a similar effect in cardiomyocytes, resulting in Ang II-induced cardiac hypertrophy. Because ACE inhibitors lower the circulating level of Ang II, they have an important clinical use as antihypertensive drugs. 78 AT1 receptor blockers are also antihypertensive, and may be particularly useful for treating stress-related disorders. 79 In EC, unlike VSMC, AT1 activation enhances endothelial nitric oxide synthetase (eNOS) activity and nitric oxide (NO) production and therefore has a vasodilatory effect. 80 Tamura et al. also found that aneurysm walls in hypertensive, oestrogen-depleted female rats showed elevated endothelial NADPH oxidase activity, while eNOS was down-regulated. They concluded that the generation of reactive oxygen species in the endothelium contributes to endothelial injury and hence the initiation of IA. 81 AT2 receptors also stimulate eNOS via the bradykinindependent pathway. 82 The vasodilator effect of Ang II is also mediated through induction of prostaglandins. 70 NO may also inhibit VSMC proliferation by inducing 3',5'-cyclic guanosine monophosphate, which subsequently activates 3',5'-cyclic adenosine monophosphate-dependent protein kinase. 83 In addition, AT2 activation inhibits EC proliferation. 74, 80 The AT2 receptor is more highly expressed in foetal than in adult tissues, implying a role in development. 84 The effects of Ang II on vascular wall structures are bidirectional, and the overall outcome of Ang II stimulation partly depends on the type of cells (EC or VSMC) that are stimulated. 84 In consequence, the RAS may exert its influence on the vasculature in two phases: a circulating phase and a local vascular phase. The circulating phase mostly involves interaction with EC and the local phase with VSMC. Circulating Ang II induces EC to generate the vasodilator NO, which also inhibits VSMC proliferation leading to vascular wall atrophy. Vascular wall Ang II stimulates VSMC proliferation. Thus, the RAS plays a complex and dual role in maintaining arterial integrity.
Other angiotensins
Ang II is the most potent but not the only effector in the RAS. 85 ACE2 (angiotensinase) catalyses the conversion of Ang II to the vasodilatory heptapeptide angiotensin-(1-7) (Ang-(1-7)), which lacks the C-terminal phenylalanine of Ang II. Treatment of hypertensive rats with olmesartan increases ACE2 mRNA and protein in the thoracic aorta. Gallagher et al. reported that Ang II down-regulates ACE2 mRNA and activity in rat aortic VSMCs; 86 Ang-(1-7) alone had no effect on ACE2 gene expression but blocked the down-regulation by Ang II. The mitogen-activated protein kinase kinase (MAPKK) inhibitor PD98059 had a similar effect. Ang II increased ERK1/ERK2 activity, and pretreatment with Ang-(1-7) vitiated the increase. Thus, the MAP kinase-phosphatase pathway regulates ACE2, maintaining the balance between Ang II and Ang- (1-7) .
The N-terminal aspartate residue of Ang II can be removed by angiotensinases in the erythrocytes and the vascular endothelium to yield Ang III, which has about one third of the vasopressor activity of Ang II but is an equally potent stimulator of aldosterone secretion.
The RAS in the brain
It is well established that the RAS is active in the brain (figure 2). 87, 88 The brain responds to both circulating and tissue Ang II, and the two response systems are integrated. 79 Ang II receptors in circumventricular organs and in cerebrovascular EC respond to circulating Ang II; there are also AT1, AT2 and AT4 receptors inside the blood-brain barrier, which respond to Ang II generated within and/or transported into the brain. AT1 receptors are predominantly found in the hypothalamic paraventricular and supraoptic nuclei, the subfornical organ, the organum vasculosum laminae terminalis, the lateral parabrachial nucleus, the ventrolateral medulla and nucleus of the solitary tract, regions that control cardiovascular function and fluid electrolyte balance; Ang II and/or Ang III appear to function as neurotransmitters or neuromodulators. 89, 90 Angiotensinogen, renin, ACE, and the aminopeptidases A and N that catalyse the generation of Ang II products may all be synthesised within the brain; angiotensinogen is mainly produced by astrocytes. 90 A prorenin receptor present in brain and other tissues promotes MAPK and ERK 1-and 2-mediated cell signalling, and receptor-bound prorenin cleaves angiotensinogen. 91 Ang II is probably involved in brain development, neuronal migration, sensory information processing, cognition and the regulation of emotional responses as well as cerebral blood flow. Most of these functions are mediated by AT1 receptors; in the adult, AT2 receptors are mostly restricted to areas involved in sensory information processing. 79 The AT4 receptor is identical to insulin-regulated aminopeptidase and has a role in memory mechanisms. 90 ACE is present in only small quantities on the plasma membranes of cerebral capillary endothelia, but it is more rapidly secreted there than in other parts of the vasculature. 92 There is evidence that release of endogenous Ang II contributes to the increase of cerebral blood flow during hypoxia. 93 Excess intracranial Ang II exerts a deleterious effect on the cardiovascular system via centres in the hindbrain, inhibiting the baroreceptor reflex and indirectly affecting renal function by altering sympathetic tone. [94] [95] [96] [97] In cases of sodium depletion, Ang II may be necessary for maintaining normal baroreflex control of vasopressin secretion. 98 Conversion to Ang III by aminopeptidase A may be necessary for the pressor effect by interacting with AT1 receptors. 99 Brainstem Ang II acutely alters sympathetic responses to afferent inputs and may be important for the integration of autonomic response patterns. Injection of Ang II into the 4 th ventricle or the rostral ventrolateral medulla (RVLM) of rabbits acutely increases renal sympathetic nerve activity (RSNA) and RSNA baroreflex responses. 100 When AT1 blockers are injected into the RVLM, the effect of Ang II on the RSNA baroreflex is inhibited, but injection into the 4 th ventricle causes sympathoexcitation. The sympathoexcitatory AT1 receptors appear to be activated during stress, surgery and anaesthesia. 101 Peripheral administration of AT1 receptor antagonists strongly affects brain circulation and normalises some of the profound alterations in cerebrovascular structure and function associated with chronic genetic hypertension, restoring normal cerebral autoregulation and cerebrovascular compliance. 79 At the same time, cerebrovascular NO synthase expression is normalised and the hypertension-induced inflammation of cerebral vessels is mitigated. These changes have been shown to make genetically hypertensive rats less vulnerable to brain ischaemia and to protect cerebrovascular flow, maintain neuron survival and markedly reduce infarct size during experimental stroke. 79 These protective effects of AT1 receptor antagonists are at least partly consequent on inhibition of the brain Ang II system, not to normalisation of blood pressure.
Ang-(1-7) is produced in the brain. 101 It appears to activate a MAPK phosphatase, stimulating eNOS expression and NO production in cerebral vessels injured by ischaemia/ reperfusion 102 and inducing relaxation of the middle cerebral artery in an endothelium-dependent manner. 103 These findings suggest a complex interplay between Ang II and Ang-(1-7), as in other parts of the vasculature, mediated by specific receptors activating different signalling pathways.
Ang III, which is also produced in the brain, has a dipsogenic effect on the subfornical organ, depresses the baroreceptor reflex, stimulates the secretion of antidiuretic hormone (ADH) and adrenocorticotropic hormone (ACTH) and also stimulates sympathetic fibres in the autonomic nervous system. 104 Thus, conversion of Ang II to Ang III in the brain may be essential for some of the physiological and pathological effects of the RAS. 
Pathophysiology of the brain RAS
The general pathophysiological significance of the endogenous intracranial RAS is well attested; for example, it makes an important contribution to the pathophysiology of congestive heart failure. 105 A detailed study by Saavedra et al. 106 showed inter alia that sustained AT1 receptor inhibition enhances the expression of AT2 receptors, which entails increased eNOS activity and NO formation and therefore enhanced vasodilatation. Inhibition of AT1 and indirect stimulation of AT2 tend to normalise cerebrovascular compliance, reduce cerebrovascular inflammation and make the brain less vulnerable to ischaemia. During progressive carotid ligation, Ang II contributes to the maintenance of cerebral blood flow by developing collateral circulation, mitigating the consequences of ischaemia. 107 Inhibition of ACE shifts the limits of cerebral blood flow autoregulation toward lower blood pressure values, apparently by blocking Ang II activity in the intima of the walls of larger arterioles, though it does not affect cerebral blood flow within the autoregulatory limits. 108, 109 This may explain the remarkable preservation of cerebral blood flow even in cases of severe hypotension accompanying chronic heart failure. 110 Exogenous Ang II, however, seems to have little discernible effect on cerebral or optic blood flow. 111 The brain RAS appears to be implicated in the development of hypertension in salt-sensitive rats. 112 Nishimura et al. measured brain angiotensinogen mRNA levels during early and late stages of hypertension induced in rats by aortic ligation between the renal arteries. 113 The mRNA levels were elevated in the lower brain stem at both stages, and in the hypothalamus on day 6 after aortic ligation, but were decreased in the cerebellum during both the early and later phases. In spontaneously hypertensive rats, angiotensinogen levels in the CSF and the brain stem were lower than in controls, and renin was elevated in the hypothalamus, brain stem, cerebral cortex and cerebellum. 68 Doursout et al. found evidence that release of an endogenous ouabain-like inhibitor of the Na + /K + pump is implicated in the effects of chronic up-regulation of the endogenous brain RAS on hypertension, 114 contributing to cardiac dysfunction after myocardial infarction 115 and susceptible to chronic central AT1-receptor blockade with losartan. 116 Conversely, chronic heart failure makes the cardiovascular centres of the hindbrain more sensitive to Ang II, and this effect appears to be mediated by TNFα, which is elevated in chronic heart failure. 117
Evidence for and against the involvement of RAS in the pathogenesis of intracranial aneurysms
There is a priori justification for the hypothesis that the RAS has a role in IA pathogenesis: several of the factors implicated in IA (hypertension, vessel geometry, apoptosis, inflammation, cell adhesion, muscle activity, ECM dynamics) are susceptible to modification by the RAS and a fortiori by ACE and AT1 blockers. There is direct evidence in support of the hypothesis. 64, 116 There is also contrary evidence, 118 but the systemic antihypertensive effect of AT1 blockers may mask their local effect on IA, which complicates the interpretation of results.
The elegant study by Ohkuma et al. on patients with ruptured and unruptured cerebral aneurysms revealed that AT1 receptor and Ang II expression was significantly downregulated in ruptured and unruptured aneurysmal walls, the decrease being more pronounced in the ruptured aneurysms. 64 These authors suggested that a decrease in the expression of RAS may result in the loss of EC and VSMC.
Alleles of the ACE gene
A study on Polish patients with aneurysmal subarachnoid haemorrhage demonstrated that the II genotype of the ACE gene was an independent risk factor for this condition (odds ratio = 4.57). 119 They attributed their finding to increased bradykinin activity associated with the II genotype of ACE. However, carrying only one I allele was not an independent risk factor for aneurysmal subarachnoid haemorrhage. 119 In contrast, a study in the UK showed an association between the I allele of ACE and increased risk of aneurysm rupture. 36 In the latter study, although the II genotype of ACE tended to be over-represented in the aneurysm group, the overall frequencies of genotypes (DD, II, DI) were not significantly different from the control group. Takenaka et al. also detected a low frequency of the DD genotype in Japanese patients with intracranial saccular aneurysm (6% versus 15% in controls); 120 these findings seem compatible with those of Slowik et al. 119 Interestingly, the II genotype of ACE is associated with lower concentrations of serum ACE than the ID or DD genotype. 121 Despite the results of these British, Polish and Japanese studies, Pannu et al. were unable to find any association between I/D polymorphisms of ACE and IA in a Caucasian population in the USA. 118 In a metaanalysis of data from the Polish, British, and American studies, Peck et al. reported an odds ratio of 1.64 (95% CI, 1.24-2.17; p =0.0003) for association between the ACE/II gene and subarachnoid haemorrhage/ruptured intracranial aneurysm under a fixed-effect model. 39 
Effects of angiotensin receptor blockers on IA development
Aneurysm formation may be inhibited by drugs that improve vascular endothelial function or protect against injury caused by haemodynamic stress. Kimura et al. examined the effects of the AT1 receptor blocker olmesartan and the statin pravastatin on the development of experimental IA in rats. 122 Pravastatin reduced both stages III (fully developed saccular aneurysms) and II+III, and olmesartan ameliorated stage III. Since pravastatin is a 3-hydroxy-3methylglutaryl-coenzyme A reductase inhibitor and olmesartan blocks AT1 and inhibits ACE, 123 it was concluded that the two drugs acted on different stages in IA pathogenesis. The findings may be applicable to humans; olmesartan appears to improve the autoregulation of cerebral blood flow in hypertensive stroke patients, irrespective of systemic blood pressure, 124 which is consistent with the role of the brain RAS in cerebral haemodynamics (see above). Drugs that inhibit the RAS in the brain reduce the incidence of stroke in patients at risk and provide neuroprotection in experimental brain ischaemia. 125 The RAS, inflammation and IA The injury to arterial walls caused by haemodynamic stress can lead to chronic inflammation and hence to further arterial wall deterioration and potentially to IA. The RAS is a major inflammatory cascade; 126 Ang II up-regulates local expression of vascular endothelial growth factor (VEGF) and its receptor, at least in the aorta, 127 and AT1 receptor blockers have anti-inflammatory effects in the brain. 128 RAS inhibitors, and other anti-inflammatories, might therefore be effective against IA. Aoki et al. found that AT1 was not up-regulated in IA walls in a rat model, and an AT1 blocker administered subcutaneously did not inhibit the inflammatory response in IA walls or IA formation. 129 They suggested that the RAS is less important in IA than aortic aneurysms, implying different mechanisms of pathogenesis in cerebral and systemic arteries.
Aldosterone may be implicated in IA Tada et al. found that the mineralocorticoid receptor blocker eplerenone reduced the incidence of IA in rats without lowering systemic blood pressure. 130 In control rats, Ang II and nitrotyrosine production were elevated in the aneurysm wall, and the mRNA levels of ACE 1, NADPH oxidase subunits, Rac1, monocyte chemoattractant protein 1 and MMP 9 were higher than in unaffected parts of the artery. Eplerenone reduced these levels, implying that aldosterone receptor antagonists block the pathogenesis of IA by inhibiting oxidative stress, inflammatory factors and local RAS activation. Thus, aldosterone receptor activation contributes to IA pathogenesis.
Subarachnoid haemorrhage is commonly associated with natriuresis and hyponatraemia, possibly indicating defective central regulation of renal sodium reabsorption with increased secretion of a natriuretic factor. 35, 112 Berendes et al. showed that salt-wasting of central origin may induce hyponatraemia in patients with aneurysmal subarachnoid haemorrhage, possibly as a result of increased secretion of brain natriuretic peptide with subsequent suppression of aldosterone synthesis. 131 One report suggests that primary aldosteronism may be a risk factor for IA. 132
Conclusions
A major obstacle to the interpretation of the results described in the previous section is that the RAS comprises an interrelated system of enzymes and substrates. A change in the activity or level of a single molecule can be offset or modulated by others. Studies should therefore take into account the possible interactions between different polymorphisms in such a multifactorial system as the RAS. Therefore, there is a need to investigate associations in patient populations between the incidence of IA with and without rupture and genetic polymorphisms in angiotensinogen, ACE, AT1 and AT2.
Many other questions about the brain RAS await answers. It is not yet clear how or where brain Ang II is synthesised, metabolised and distributed, and the role of brain AT2 receptors in adults remains mysterious. The molecular mechanisms responsible for inflammation and cerebrovascular remodelling when AT1 receptors are stimulated merits investigation. The relationship between the brain RAS and susceptibility to stress and brain ischaemia is another promising area for future study. All these lines of investigation are likely inter alia to elucidate the role of the RAS in the pathogenesis of IA.
